Scott Hiebert
Vanderbilt-Ingram Cancer Center (VICC)
Department of Biochemistry
We use state-of-the-art genomic methods to define the molecular mechanisms of action of mutations associated with acute myeloid leukemia and B-cell lymphoma. By coupling these genomic methods with CRISPR-based approaches to add sequences that allow rapid degradation of the endogenous transcription factors, we can certify these factors that are frequently mutated as therapeutic targets.
We use state-of-the-art genomic methods to define the molecular mechanisms of action of mutations associated with acute myeloid leukemia and B-cell lymphoma. By coupling these genomic methods with CRISPR-based approaches to add sequences that allow rapid degradation of the endogenous transcription factors, we can certify these factors that are frequently mutated as therapeutic targets.
Keywords: t(8 , 21) , AML1-ETO , FOXO1 , HDAC3 , Chromatin-modifying enzymes , Jmjd1c
Research Area: Gene Regulation , Genomics , Cancer Biology